anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ischemia-reperfusion (IR) injury remains a pivotal contributor to myocardial damage following acute coronary events and revascularization procedures. Phosphoinositide 3-kinase (PI3K), a key mediator of cell survival signaling, plays a central role in regulating inflammatory responses and cell death mechanisms. Trans-chalcone (Tch), a natural compound known for its anti-inflammatory activities, has shown promise in various disease models. The aim of the current study was to investigate the potential protective effects of Tch against myocardial injury induced by ischemia and reperfusion challenges by targeting the PI3K-inflammasome interaction. Experimental models utilizing male rats subjected to an in vivo model of IR injury and myocardial infarction were employed. Administration of Tch (100 μg/kg, intraperitoneally) significantly reduced myocardial injury, as indicated by limited infarct size and decreased levels of the myocardial enzyme troponin. Mechanistically, Tch upregulated PI3K expression, thereby inhibiting the activity of the NOD-like receptor protein 3 inflammasome followed by the activation of pro-inflammatory cytokines interleukin-1β (IL-1β) and IL-18. Moreover, it mitigated oxidative stress and suppressed vascular-intercellular adhesion molecules, contributing to its cardioprotective effects. The PI3K/Akt pathway inhibitor LY294002 considerably attenuated the beneficial effects of Tch. These findings highlight the therapeutic potential of Tch in ameliorating myocardial injury associated with IR insults through its modulation of the PI3K/Akt-inflammasome axis. The multifaceted mechanisms underlying its protective effects signify Tch as a promising candidate for further exploration in developing targeted therapies aimed at mitigating ischemic heart injury and improving clinical outcomes in cardiovascular diseases characterized by IR injury.
The 27 patients were recruited for the study, aged 45 to 70 years, who had undergone lumbar spine fusion. The patients were randomized in to two groups. The strength training group started rehabilitation 3 weeks after surgery. The patients exercised two times per week, over 9 weeks. The focus was on muscle activation of lumbopelvic muscles stabilization. The control group followed a standard postoperative protocol, where no exercises were performed at the rehabilitation stage. The functional outcomes and the plain radiographs were evaluated after 3 weeks and subsequently after 3 and 18 months after the surgery.
FIELD: medicine, chemical-pharmaceutical industry, pharmacy. SUBSTANCE: invention relates to improvement of medicinal form of glycyrram tablet. Proposed medicinal form comprises glycyrram as an active component and the following accessory substances: glucose, calcium stearate and precipitated calcium carbonate taken in the definite ratios. Tablets show the improved bioavailability and enhanced stability. EFFECT: improved properties of medicinal form. 1 cl, 2 tbl, 3 ex
Child's respiratory impedance will be continuously recorded using the Leo device during hospital/ED stay after consent and enrollment, and then during 7 days at home after discharge. The Leo device provides no intervention, and will only monitoring chest impedance for the worn period. Oscillometry and spirometry testing and flow volume assessment using PNT will be performed during study visits with Leo device attached.
Drawing from prior studies, we conducted a sample size calculation for a predictive model using the website https://mvansmeden.shinyapps.io/BeyondEPV/. By setting the number of candidate predictors to 9, the events fraction to 0.14, and the criterion value for rMPSE to 0.04, we determined that a minimum total sample size of 900 is required, with a minimally expected event per variable of 13.9. All patients were classified into either the CI-PONV group or the non-CI-PONV group. All 56 perioperative clinical features, encompassing baseline characteristics, preoperative conditions, and intraoperative information, were considered as potential predictive factors. In the quest to uncover potential predictive factors associated with CI-PONV, we employed the least absolute shrinkage and selection operator (LASSO) to sift through clinically significant variables. Subsequently, we utilized stepwise regression based on the Akaike Information Criterion (AIC) to further refine the selection of the ultimate predictors. Finally, a logistic regression model was developed based on the selected factors influencing CIPONV. The discrimination of the model was assessed by the ROCAUC and the goodness of fit of the model was evaluated using the Hosmer-Lemeshow test and calibration plots. A nomogram based on the logistic regression model output was developed as a tool for clinical application.
The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions to patient with overweight or obesity who have completed the VA San Diego MOVE program.
BACKGROUND: One of the recognized issues faced by cancer survivors is increasing weight. Weight gain has been associated with an increased death rate in cancer survivors. Research on weight gain among breast cancer survivors (BCS) is scarce in Nigeria.
AIM: To assess the weight changes and its associated factors in breast cancer survivors (BCS).
MATERIALS AND METHODS: A total of 98 breast cancer survivors attending the Radiation Oncology clinic were recruited. Sociodemographic variables, treatment history, weight at presentation, and present weight were obtained. Patients were then categorized into three groups: weight gain (>5% increase), stable weight (-5 to 5% change), or weight loss (>5% decrease).
RESULT: The present mean weight and BMI were significantly higher than at presentation (75.14±17.59 kg vs 76.88±17.42 kg, p=< 0.0001) and (28.74 ± 6.30 vs 29.42 ±6.20, < 0.0001) respectively. Only 28 (29.6%) gained weight, 65 (66.3%) maintained stable weight while 5 (5.1%) lost weight. On univariate analysis, older age, living with partners, presence of comorbidity, year of last chemotherapy less than one year, and hormonal therapy use were associated with weight gain. Multivariate analysis revealed that the presence of comorbidities, patients receiving the last chemotherapy less than a year from the time of recruitment, and hormonal therapy were independently associated with weight gain.
CONCLUSION: About a quarter of BCS gained weight. Older age, presence of comorbidity, year of last chemotherapy less than one year, and hormonal therapy use were associated with weight gain. The weight of cancer survivors should be monitored regularly during follow-up visits.
A system for managing prescriptions via a blockchain is provided. Prescription information relating to a prescription is displayed. Submission information for the pharmacy relating to dispensing the prescription is displayed for each of a plurality of pharmacies. Selection of a pharmacy to dispense the prescription is received, where a prescription transaction relating to the prescription is recorded in a blockchain. An indication that a dose was taken is received from the patient after the prescription is dispensed by the selected pharmacy selected. A dose token transaction is recorded in the blockchain.
The specific gamma ray constant for Tc 99m is 0.78 R/hr-millicurie at 1 cm. The first half-value layer is 0.017 cm of lead (Pb). A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 2. For example, the use of a 0.25 cm thickness of Pb will attenuate the radiation emitted by a factor of about 1,000.

To correct for physical decay of this radionuclide, the fractions that remain at selected intervals after the time of calibration are shown in Table 3.

* Calibration time
Many Marines and Sailors return from deployment with mental health problems related to their experiences. One such problem is posttraumatic stress disorder (PTSD), which involves symptoms such as persistent unwanted memories of traumatic events, avoidance of reminders of the events, excessive watchfulness, jumpiness and irritability. Current therapies for PTSD focus chiefly on fear related to life-threat and were developed chiefly on civilians. We developed and piloted tested a psychological treatment for PTSD specifically for service members who suffer not only life-threat, but also traumatic loss and inner conflicts from morally challenging experiences. This intervention, Adaptive Disclosure (AD) is an eight-session PTSD treatment that helps Marines to identify unhelpful beliefs about a traumatic event and find ways to move forward. Preliminary clinical data suggests that AD is acceptable to Marines, feasible to implement, and safe and that it reduces PTSD and depression. The primary objective of this randomized controlled non-inferiority trial is to determine whether or not AD is as least as effective as Cognitive Processing Therapy, cognitive only version (CPT-C), which is an empirically validated and commonly used PTSD treatment.

We plan to recruit 266 Marines for this project. They will be randomly assigned to AD or CPT-C and followed during and after treatment. The groups will be compared on measures of mental health (particularly PTSD and depression), work-related functioning, trauma-related beliefs, coping and attitudes about mental health care.
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention discloses stable in storage in an aqueous medium particles with the definite form of allotropic organic compounds. Particles can be shaped in correspondence with the required application. Preferable forms of such particles are microspheres being especially having diameter from about 1 to about 1000 microns. Stable particles with the definite form are especially suitable for preparing pharmaceutical compositions being especially when the sustained release and uniform bioavailability are necessary. Storage-stable particles are prepared by crystallization allotropic organic compounds from the solid state. Crystallization process from the solid state gives tools for providing stability. Invention provides stability of crystalline form of indicated allotropic compound in storage in an aqueous medium for at least one month being without deterioration of the parent particles size. EFFECT: improved preparing method. 40 cl, 10 ex
After hematopoietic stem cell transplantation, chimerism assay is a useful approach to monitor the success of the transplant and to select the appropriate treatment strategy, such as donor leukocyte infusion or immunosuppressive drug dosage. Short tandem repeat PCR is the method that has been accepted as the gold standard for chimerism. However, it has not yet been sufficient to detect mixed chimerism in patients with minimal residual disease. Simultaneously, recent years have been marked by developing sensitive, high-throughput, and accurate molecular genetic assays. These novel methods have subsequently been adapted for the analysis of post-transplant chimerism. In this review, we discuss the technical features of both novel and conventional gold standard chimerism assays. We also discuss their advantages and disadvantages.
PURPOSE: The use of robotic assisted surgery is increasing but training residents in its use may be associated with increased operative time and cost. The objective of this study is to compare the operative time of robotic incisional/ventral hernia repair (RIVHR) and robotic inguinal hernia repair (RIHR) when performed with and without a resident or fellow trainee.
METHODS: A review of prospectively collected data was performed on all patients who underwent RIVHR and RIHR by a single surgeon over a 9-year period (2014-2023). Study variables included presence of trainee (resident or fellow), procedure time, console time, and recurrent hernia. Primary outcomes include procedure time and console time.
RESULTS: A total of 402 surgeries were included for analysis. Residents assisted in 190 (47%) of the procedures, while fellows assisted in 97 (24%), and 115 (29%) were performed without a trainee. Median (IQR) console times in RIVHR assisted by fellows was 102 (72-145) minutes, compared to 90 (71-129) minutes among surgeries assisted by residents and 65 (52-82) minutes among surgeries performed without a trainee (p < 0.0001), a similar trend was observed for RIHR. The duration of hernia repair assisted by trainees was significantly longer than surgeries performed without a trainee.
CONCLUSION: Operative time for RIVHR and RIHR is significantly lower when performed without a trainee. However, RIHR assisted by residents showed a consistent decrease in operative time over the 9-year period.
Electrolyte deficits, particularly in serum potassium and phosphate, may occur during prolonged use of concentrated dextrose solutions.

Depending on the volume and rate of infusion, the intravenous administration of dextrose solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations (including hypoosmotic hyponatremia, overhydration, congested states or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations in the administered solution. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations in the solution.

Avoid Dextrose Injection in patients with or at risk for fluid and/or solute overloading. If use cannot be avoided, monitor fluid balance, blood electrolyte levels, concentration of glucose, acid-base balance, correct fluid and electrolyte imbalances during prolonged parenteral therapy or whenever the condition of the patient or the rate of administration warrants such evaluation. Additional monitoring is recommended for patients with water and electrolyte disturbances that could be aggravated by increased glucose, insulin administration and/or free water load. 

Patients at increased risk for developing hyponatremic encephalopathy include pediatric patients; elderly patients, women, in particular premenopausal women; patients with hypoxemia; and patients with underlying CNS disease [see Use in Specific Populations (8.4,8.5)].
Participants topically applied EVICEL, which consisted of component 1: Concentrate of human fibrinogen (BAC 2) (55-85 mg/mL) and component 2: human thrombin (800-1200 IU/mL) solutions. The 2 components (BAC2 and thrombin) were mixed and applied topically.
PURPOSE:To obtain a base for solid drug reparation, capable of freely controlling the release of the drug and having both rapid-releasing and slow-releasing activity to a drug, by dissolving a pH-dependent enteric polymer under specific condition in a polyalkylene glycol which is solid at room temperature. CONSTITUTION:The objective base can be produced by dissolving (A) a pH- dependent enteric polymer (e.g. cellulose acetate phthalate) having the following characteristics in (B) a polyalkylene glycol (e.g. polyethylene glycol) which is solid at room temperature, preferably at <=40 deg.C. The enteric polymer is (i) soluble in said polyalkylene glycol, (ii) soluble in water at 5-7pH and (iii) hardly soluble in water compared with said polyalkylene glycol. The dissolution can be carried out either by heating and melting the polyalkylene glycol and dissolving the pH-dependent polymer in the melt, or by dissolving the polymer using a solvent. A drug is added to the base and the mixture is formed in the from of a solid drug, especially a suppository, etc.
Participants in the Standard of Care arm will receive methotrexate and other disease modifying antirheumatic drugs as per local treatment guidelines and study doctor's judgement. Adalimumab may be initiated after a minimum of 6 months.
The invention discloses a traditional Chinese medicine composition for treating hemorrhoids. The traditional Chinese medicine composition is characterized by being processed and prepared through the following traditional Chinese medicine crude drugs, by weight, 20-80 parts of radix asparagi, 20-80 parts of cortex mori radicis, 20-80 parts of rhubarb, 20-80 parts of tabasheer and 2-8 parts of borneol. The pharmaceutical composition has the good analgesic effect, the good anti-inflammation effect, the good hemostasis effect and the good bacteriostasis effect. The composition is safe to use, and is used for clinic after being proved that no toxic and side effects are generated on the skin. The pharmaceutical composition is mainly used for treating internal and external hemorrhoids accompanied by bleeding, anal fissure and the like in clinic, and has good and rapid hemostasis, analgesis, anti-inflammation, astringency and detumescence effects. The composition is wide in medicinal herb resource, simple in processing of preparations, low in price, safe and effective in clinic application, good in stability, convenient to popularize and capable of being easily accepted by patients.
Apolipoprotein E (ApoE) is involved in cholesterol transport among cells and also plays an important role in amyloid formation, co-depositing with amyloid fibrils in various types of amyloidosis. Although the in vivo amyloidogenicity of ApoE has not been previously demonstrated, this study provides evidence of ApoE amyloidogenicity in leopard geckos (Eublepharis macularius), belonging to the class Reptilia. Histologically, amyloid deposits were localized within cholesterol granulomas and exhibited positive Congo red staining, with yellow to green birefringence under polarized light. On mass spectrometry-based proteomic analysis, ApoE was detected as a dominant component of amyloid; of the full length of the 274 amino acid residues, peptides derived from Leu185-Arg230 were frequently detected with non-tryptic truncations. Immunohistochemistry with anti-leopard gecko ApoE antibody showed positive reactions of amyloid deposits. These results show that ApoE is an amyloid precursor protein within the cholesterol granulomas of leopard geckos. Although further investigations are needed, the C-terminal region of ApoE involved in amyloid formation is a lipid-binding region, and there should be a relationship between amyloidogenesis and the development of cholesterol granulomas in leopard geckos. This study provides novel insights into the pathogenesis of ApoE-related diseases.
BACKGROUND: The global burden of obesity has reached epidemic proportions, placing great strain on the North American healthcare system. We designed a retrospective cohort database study comparing postoperative morbidity and healthcare resource utilization between patients living with and without obesity undergoing surgery for colorectal cancer.
METHODS: Adult patients undergoing resection for colorectal cancer were identified from the 2015 to 2019 National Inpatient Sample database. Patients were stratified according to obesity status (i.e., body mass index of 30 kg/m2). Propensity score matching (PSM) with 1:1 nearest-neighbour matching was performed according to demographic, operative, and hospital characteristics. The primary outcome was postoperative morbidity. Secondary outcomes included system-specific postoperative complications, postoperative mortality, length of stay, total admission healthcare cost, and post-discharge disposition. McNemar's and Wilcoxon matched pairs signed rank tests were performed.
RESULTS: After PSM, 7565 non-obese and 7565 obese patients were included. Patients with obesity had a 10% increase in relative risk of overall in-hospital postoperative morbidity (23.1% versus 25.6%, P = 0.0015) and a $4564 increase in hospitalization cost ($70 248 USD versus $74 812 USD, P = 0.0004). Patients with obesity were more likely to require post-operative ICU admission (5.0% versus 8.0%, P < 0.0001) and less likely to be discharged home after their index operation (68.3% versus 64.2%, P = 0.0022).
CONCLUSION: Patients with obesity undergoing surgery for colorectal cancer may be at an increased risk of in-hospital postoperative morbidity. They may also be more likely to have increased hospitalization costs, post-operative ICU admissions, and to not be discharged directly home. Preoperative optimization via weight loss strategies should be further explored.
Chronic neck pain is one of the pains with the highest prevalence these days due to the imprecise daily life routine of people including students \& office workers etc. It is generally declared that pain and stiffness in neck occur due to faulty posture for prolonged periods of time against the gravity. Deep layered muscles e.g longus capitus, longus Colli, rectus capitus anterior \& rectus capitus lateralis provides the stability to neck if they are targeted it is believed that the observed problem can be cured. This study is aimed to compare two methods for stability of neck i.e. core stability exercises \& swiss ball exercises.

Until now many treatment options have been used for chronic neck pain e.g stretching, isometrics, fascia release, mobilization techniques etc, and in recent literature, it is seen that stability of neck muscles are emerging to alleviate chronic neck pain. This study is aiming to compare the effects of core stability exercises and swiss ball exercises.So, the latest , effective and economical options for treatment can be used by the physical therapists and can be guided to the patients in order to gain long-lasting effects.
The optimal daily dose of calcitriol capsules must be carefully determined for each patient. Calcitriol can be administered orally as a capsule (0.25 mcg or 0.50 mcg). Calcitriol therapy should always be started at the lowest possible dose and should not be increased without careful monitoring of serum calcium.

The effectiveness of calcitriol capsule therapy is predicated on the assumption that each patient is receiving an adequate but not excessive daily intake of calcium. Patients are advised to have a dietary intake of calcium at a minimum of 600 mg daily. The U.S. RDA for calcium in adults is 800 mg to 1200 mg. To ensure that each patient receives an adequate daily intake of calcium, the physician should either prescribe a calcium supplement or instruct the patient in proper dietary measures.

Because of improved calcium absorption from the gastrointestinal tract, some patients on calcitriol may be maintained on a lower calcium intake. Patients who tend to develop hypercalcemia may require only low doses of calcium or no supplementation at all.

During the titration period of treatment with calcitriol, serum calcium levels should be checked at least twice weekly. When the optimal dosage of calcitriol has been determined, serum calcium levels should be checked every month (or as given below for individual indications). Samples for serum calcium estimation should be taken without a tourniquet.